- Egypt rights center raided, 2 Mubaraks acquitted
- New Mexico Supreme Court rules same-sex marriage constitutional
- Blame Bush: 5 years later, that’s still the mantra, pollsters find
- Dutch prostitutes demand same retirement benefits as soccer stars
- John McCain to Harry Reid: I’ll ‘kick the crap’ out of you
- Dogs that talk: Researchers seek $10K for ‘No More Woof’ technology
- 1,000 firefighters called to battle stubborn Big Sur wildfire
- Black Friday brouhaha: Millions of Target shoppers hit by credit card theft
- Britain orders airplane to rescue citizens from violent South Sudan
- Mega Millions winner emerges as Georgia mom, in ‘disbelief’
By Andrew P. Napolitano
Fourth Amendment says Obama is not at liberty to collect metadata
Independent voices from the The Washington Times Communities
Topic - Timothy Anderson
A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. said Monday that it will continue to study its effect on a different group of patients.
Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit Tuesday as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government because of the health care overhaul.
he noted that bapineuzumab and similar drugs have been viewed as "highly likely to fail and so far this assumption has been correct."
Successful Alzheimer's drugs "could be the next Lipitors _ in terms of their size _ should they work ," says Bernstein Research analyst Dr. Timothy Anderson.